Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tonix Pharm Holdings
(NQ:
TNXP
)
0.1460
+0.0094 (+6.88%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
207,616,138
Open
0.1751
Bid (Size)
0.1422 (1)
Ask (Size)
0.1430 (2,854)
Prev. Close
0.1366
Today's Range
0.1434 - 0.2124
52wk Range
0.1300 - 22.14
Shares Outstanding
22,004,159
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
What's Going On With Tonix Pharmaceuticals Stock Friday?
September 27, 2024
Tonix shares are trading higher Friday after the company announced the United States Patent and Trademark Office granted a patent covering the subcutaneous delivery of Zembrace Symtouch for treating...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp.’s (NASDAQ: TNXP) Receives New US Patent for Subcutaneous Administration of Zembrace(R) SymTouch(R) to Treat Migraines
September 27, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Performance
YTD
-98.91%
-98.91%
1 Month
-36.24%
-36.24%
3 Month
-80.05%
-80.05%
6 Month
-97.60%
-97.60%
1 Year
-99.15%
-99.15%
More News
Read More
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Participate in Global Conference with Three TNX-102 SL Data Presentations
September 23, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Awarded Patent Covering Intranasal Delivery of FDA-Approved Tosymra to Treat Migraines
September 19, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Looking Into Tonix Pharmaceuticals's Recent Short Interest
September 19, 2024
Via
Benzinga
As Research Into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront – Tonix Targets It With FDA-Fast Track-Designated TNX-102 SL
September 04, 2024
Via
ACCESSWIRE
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp.’s (NASDAQ: TNXP) TNX-801 Positioned as Viable Contender in Global Fight Against Mpox
September 18, 2024
Via
Investor Brand Network
Exposures
Product Safety
New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution
September 18, 2024
Via
ACCESSWIRE
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports TNX-801 Aligns with WHO Preferred TPP for Mpox Vaccines
September 16, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Names Seasoned Veteran as New EVP of Commercial Operations
September 10, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Preclinical Data Demonstrating TNX-801’s Single-Dose Immune Protection Against Mpox
September 09, 2024
Via
Investor Brand Network
Exposures
Product Safety
What's Going On With Tonix Pharmaceuticals (TNXP) Stock?
September 09, 2024
Via
Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
September 09, 2024
Via
Benzinga
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Launches Educational Campaign to Inspire Patients to Optimize Migraine Treatment Plans with Non-Oral Medication
September 06, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Developing Fast-Track-Designated Treatment for Fibromyalgia
September 04, 2024
Via
Investor Brand Network
Exposures
Product Safety
Tonix Pharma Collaborates With World's Largest Vaccine Manufacturer For Mpox Vaccine
August 26, 2024
Via
Benzinga
Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix’s Mpox Vaccine, TNX-801
August 26, 2024
Via
FinancialNewsMedia
Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global Emergency
August 23, 2024
Via
ACCESSWIRE
What's Going On With Tonix Pharmaceuticals (TNXP) Stock?
August 20, 2024
Via
Benzinga
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
August 19, 2024
Via
Benzinga
TNXP Stock Earnings: Tonix Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
August 16, 2024
Via
InvestorPlace
Tonix Pharmaceuticals' Live Virus Vaccine Candidate Shows Long-Term Protection From Mpox, Smallpox With 1 Dose, Animal Study Suggests
August 16, 2024
Via
Benzinga
FDA Recognizes Fibromyalgia as a 'Serious Condition' And Fast-Tracks New Drug Candidate
August 01, 2024
Via
ACCESSWIRE
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024
Via
FinancialNewsMedia
Exposures
Product Safety
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.